Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $850 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice TargetHot
Argus Research analyst Jasper Hellweg upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $850 price target.
Argus Research analyst Jasper Hellweg upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $850 price target.